Bristol-Myers Squibb Company (BMY) Return on Equity (ROE): 36.25%
Is Bristol-Myers Squibb Company’s return on equity (ROE) high or low?
Bristol-Myers Squibb Company's return on equity (ROE) of 36.25% is 714% above its 5-year average of 4.45%, near the high end of its 5-year range (-54.78%–38.18%).
As of Thursday, June 11, 2026. 536.75% above its 12-month average of -8.30%.
BMY Return on Equity (ROE) Chart
BMY Average Return on Equity (ROE) Chart
BMY Current vs Average Return on Equity (ROE) Chart
BMY Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
36.25%
RETURN ON EQUITY (ROE) AVG TTM
-8.30%
RETURN ON EQUITY (ROE) AVG 3Y
7.76%
RETURN ON EQUITY (ROE) AVG 5Y
4.45%
RETURN ON EQUITY (ROE) AVG 10Y
10.50%
RETURN ON EQUITY (ROE) AVG 15Y
12.71%
RETURN ON EQUITY (ROE) AVG 20Y
18.13%
CURRENT VS TTM AVG
+536.75%
CURRENT VS 3Y AVG
+367.14%
CURRENT VS 5Y AVG
+714.00%
CURRENT VS 10Y AVG
+245.09%
CURRENT VS 15Y AVG
+185.25%
CURRENT VS 20Y AVG
+99.90%
BMY Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | $116.13B | 36.25% | -8.30% | 7.76% | 4.45% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 22.41% | 8.96% | 15.60% | 19.47% |
| Danaher Corporation (DHR) | $126.39B | 6.97% | 7.38% | 9.51% | 10.24% |
| CVS Health Corporation (CVS) | $126.70B | 3.79% | 4.23% | 6.35% | 7.74% |
| Medtronic plc (MDT) | $102.72B | 9.80% | 4.86% | 6.08% | 6.82% |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 17.05% | 15.07% | 13.91% | 13.46% |
| Elevance Health Inc. (ELV) | $86.47B | 11.94% | 13.69% | 14.71% | 14.93% |
| Pfizer Inc. (PFE) | $149.61B | 8.31% | 9.04% | 13.32% | 16.07% |
| Cigna Corporation (CI) | $77.92B | 14.90% | 11.32% | 12.19% | 12.83% |
| Abbott Laboratories (ABT) | $155.75B | 12.06% | 20.32% | 18.59% | 17.97% |
Return Analysis
ROE
36.3%
ROA
8.4%
Bristol-Myers Squibb Company Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?
- The return on equity (ROE) for BMY stock is 36.25%.
- Is Bristol-Myers Squibb Company's return on equity (ROE) high or low?
- Bristol-Myers Squibb Company's return on equity (ROE) of 36.25% is 714% above its 5-year average of 4.45%, near the high end of its 5-year range (-54.78%–38.18%).
- What is the TTM average return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?
- The TTM average return on equity (ROE) for BMY stock is -8.30%.
- What is the 3Y average return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?
- The 3Y average return on equity (ROE) for BMY stock is 7.76%.
- What is the 5Y average return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?
- The 5Y average return on equity (ROE) for BMY stock is 4.45%.
- What is the 10Y average return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?
- The 10Y average return on equity (ROE) for BMY stock is 10.50%.
- What is the 15Y average return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?
- The 15Y average return on equity (ROE) for BMY stock is 12.71%.
- What is the 20Y average return on equity (ROE) for Bristol-Myers Squibb Company (BMY)?
- The 20Y average return on equity (ROE) for BMY stock is 18.13%.
Bristol-Myers Squibb Company Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 38.18% |
| 2024-12-31 | -54.78% |
| 2023-12-31 | 27.27% |
| 2022-12-31 | 20.37% |
| 2021-12-31 | 19.46% |
| 2020-12-31 | -23.78% |
| 2019-12-31 | 6.66% |
| 2018-12-31 | 35.07% |
| 2017-12-31 | 8.58% |
| 2016-12-31 | 27.55% |
| 2015-12-31 | 10.97% |
| 2014-12-31 | 13.49% |
| 2013-12-31 | 16.91% |
| 2012-12-31 | 14.39% |
| 2011-12-31 | 23.25% |
| 2010-12-31 | 19.74% |
| 2009-12-31 | 71.49% |
| 2008-12-31 | 42.86% |
| 2007-12-31 | 20.50% |
| 2006-12-31 | 15.86% |
| 2005-12-31 | 26.77% |
| 2004-12-31 | 23.41% |
| 2003-12-31 | 31.74% |
| 2002-12-31 | 24.41% |
| 2001-12-31 | 53.27% |
| 2000-12-31 | 51.32% |
| 1999-12-31 | 48.20% |
| 1998-12-31 | 41.46% |
| 1997-12-31 | 44.40% |
| 1996-12-31 | 43.38% |
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner